Stockscreener 앱 받기
28.92
0.45%
-0.0889
전일 마감가:
$29.01
열려 있는:
$29.17
하루 거래량:
211.09K
Relative Volume:
0.54
시가총액:
$535.36M
수익:
$294.28M
순이익/손실:
$367.02M
주가수익비율:
1.5293
EPS:
18.9115
순현금흐름:
$75.66M
1주 성능:
+2.05%
1개월 성능:
-4.66%
6개월 성능:
-43.33%
1년 성능:
+52.40%
1일 변동 폭
$28.51
$29.34
1주일 범위
$27.88
$29.70
52주 변동 폭
$18.14
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
명칭
Rigel Pharmaceuticals
전화
650-624-1100
주소
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
28.93 | 536.75M | 294.28M | 367.02M | 75.66M | 18.91 |
VRTX
Vertex Pharmaceuticals Inc
|
436.88 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.94 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.98 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.22 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.85 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-04-03 | 재개 | Piper Sandler | Neutral |
| 2022-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-08 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 개시 | B. Riley Securities | Neutral |
| 2020-11-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 재개 | JP Morgan | Overweight |
| 2019-03-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 개시 | Citigroup | Buy |
| 2018-05-02 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 재개 | Piper Jaffray | Overweight |
| 2017-12-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 재개 | H.C. Wainwright | Buy |
| 2017-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-31 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 재확인 | Piper Jaffray | Overweight |
| 2016-07-13 | 개시 | H.C. Wainwright | Buy |
| 2016-06-13 | 개시 | Piper Jaffray | Overweight |
| 2016-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 재확인 | Stifel | Buy |
| 2012-11-29 | 개시 | UBS | Neutral |
| 2012-11-06 | 재확인 | Oppenheimer | Outperform |
| 2012-03-26 | 개시 | Canaccord Genuity | Hold |
| 2010-12-10 | 다운그레이드 | MP Advisors | Outperform → Market Perform |
모두보기
Rigel Pharmaceuticals 주식(RIGL)의 최신 뉴스
[144] RIGEL PHARMACEUTICALS INC SEC Filing - Stock Titan
RIGL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $57 - GuruFocus
RIGL Stock Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Rigel Pharmaceuticals Presents GAVRETO Phase 3 Data at ASCO 2026 - Intellectia AI
META_TITLE_QUOTE - Yahoo Finance
Rigel cancer drugs post multi-year responses in lung and relapsed leukemia - Stock Titan
Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock? - MSN
RIGL Stock Price, Quote & Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story - Yahoo Finance
Rigel Pharmaceuticals, Inc. (RIGL) M&A CallSlideshow (NASDAQ:RIGL) 2026-05-20 - Seeking Alpha
Rigel Shareholders Approve Equity Plans and Board Slate - TipRanks
Rigel (RIGL) investors back equity plan, ESPP and auditor at 2026 meeting - Stock Titan
Rigel Pharmaceuticals Highlights Growth Amid Rising Costs - TipRanks
Pfizer Keeps Oncology Upside As Rigel Takes VEPPANU PROTAC Lead - simplywall.st
RIGEL (RIGL) director Kamil Ali-Jackson receives 5,750-share RSU board grant - Stock Titan
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug - MSN
Rigel Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Rigel Pharmaceuticals Q3 2025 Earnings Preview - MSN
Avoiding Lag: Real-Time Signals in (RIGL) Movement - Stock Traders Daily
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GuruFocus
Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy - MSN
Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Rigel Pharmaceuticals (RIGL) Is Up 11.4% After Licensing FDA‑Approved Breast Cancer Drug VEPPANU - simplywall.st
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer - Yahoo Finance
Armistice Capital (RIGL) reports 1.28M shares, 6.93% stake - Stock Titan
Weekly Buzz: Lilly Posts Positive Trial Data, Rigel Licenses PROTAC Drug, BMY Strikes $15.2B Deal - RTTNews
Rigel Pharmaceuticals inks worldwide agreement to develop and commercialize VEPPANU - Traders Union
Rigel Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference - Moomoo
These Analysts Increase Their Forecasts On Arvinas After Q1 Results - Sahm
Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, ArvinasHas The Bull Case Changed? - Yahoo Finance
RIGL Maintained by Citigroup -- Price Target Raised to $81.00 - GuruFocus
Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu | PharmExec - Pharmaceutical Executive
Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu - Pharmaceutical Executive
New Haven biotech Arvinas signs potential $405M drug licensing deal - Hartford Business Journal
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $81 - Moomoo
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Raises Target Price to $81 - Moomoo
Rigel snaps up breast cancer drug Veppanu in up to $405m deal - The Pharma Letter
Rigel Pharmaceuticals Enters License Agreement for VEPPANU™ with Arvinas and Pfizer – 8-K Filing Details - Minichart
Pfizer PROTAC Licensing Deal With Rigel Adds Royalties To Valuation Story - simplywall.st
[8-K] RIGEL PHARMACEUTICALS INC Reports Material Event - Stock Titan
Rigel Pharmaceuticals inks deal with Arvinas and Pfizer for breast cancer drug VEPPANU, shares jump 10.7%. - Pluang
Pfizer (PFE) Enters Licensing Deal with Rigel Pharmaceuticals - GuruFocus
Rigel Pharmaceuticals stock rises on Veppanu licensing deal - Investing.com
Why Is Rigel PharmaceuticalsArvinas (NASDAQ:ARVN), Pfizer (NYSE:PFE), Rigel Pharmaceuticals (NASDAQ:RI - Benzinga
Arvinas, Pfizer, and Rigel Partner on Veppanu (Vepdegestrant) Breast Cancer Drug - geneonline.com
Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu - TipRanks
Biopharma bites: Rigel buys beleaguered PROTAC, Bayer's pipeline trim, and more from Novo Nordisk, Delos Capital - FirstWord Pharma
RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside? - Stocktwits
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug - BioPharma Dive
Coming through on Veppanu with back-loaded Rigel deal - BioWorld News
Rigel Pharmaceuticals (RIGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rigel Pharmaceuticals 주식 (RIGL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MOOS WALTER H | Director |
Feb 20 '26 |
Option Exercise |
24.00 |
4,000 |
96,000 |
16,722 |
| MOOS WALTER H | Director |
Feb 20 '26 |
Sale |
36.36 |
4,000 |
145,440 |
12,722 |
2.25%
0.46%
자본화:
|
볼륨(24시간):